Soleno Therapeutics(SLNO)
REDWOOD CITY, CABiotechnology
Focus: Soleno Therapeutics is a public biotechnology company focused on rare metabolic diseases, with a marketed small molecule product (VYKAT XR) and a Phase 3 pipeline concentrated in Prader-Willi Syndrome and related obesity disorders.
Profile data last refreshed 35m ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Total Funding
$NaNB
Open Jobs
4-2 this month
Stable — net -2 jobs in 30d
2 added, 4 removed. Backfill posture.
Should You Work at Soleno Therapeutics?
AI assessmentSoleno represents a window into a late-stage biotech acquisition: suitable for professionals seeking commercial-stage rare disease expertise, but acquisition status requires clarity on role permanence and integration timeline.
Why Work Here
- Company generated $190M in FY 2025 revenue with an approved commercial product (VYKAT XR), providing stability beyond pre-revenue stage risk.
Data completeness
7/9 — Strong
Company HealthStrong
Pipeline
Late-stage
4 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$190M
Key Products
Growth9.1yr
First and only approved product generating $190M FY 2025 revenue; provides commercial foundation and 10-year patent exclusivity runway.
Help build intelligence for Soleno Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.